Search company, investor...
MiraDx company logo


Founded Year



Series A | Alive

Total Raised


Last Raised

$1M | 13 yrs ago

About MiraDx

Mira Dx is a genomics company dedicated to the development and commercialization of novel microRNA-based diagnostic tests.

Headquarters Location

11600 Wilshire Blvd., Suite 410

Los Angeles, California, 90025,

United States


Missing: MiraDx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MiraDx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing MiraDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MiraDx is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

MiraDx Patents

MiraDx has filed 5 patents.

The 3 most popular patent topics include:

  • Oncology
  • Cancer treatments
  • Experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics




Cancer treatments, Immunology, Clusters of differentiation, Psychedelic phenethylamines, Substituted amphetamines


Application Date


Grant Date



Related Topics

Cancer treatments, Immunology, Clusters of differentiation, Psychedelic phenethylamines, Substituted amphetamines



Latest MiraDx News

UCLA Jonsson Comprehensive Cancer Center scientists identify germline signature that predicts side effects from anti-PD1/PDL1 checkpoint therapy

Feb 3, 2022

UCLA Jonsson Comprehensive Cancer Center scientists identify germline signature that predicts side effects from anti-PD1/PDL1 checkpoint therapy Investigators from UCLA Jonsson Comprehensive Cancer Center have identified a germline biomarker signature that successfully predicts which patients will suffer serious side effects that occur in up to 3 in ten patients on anti-PD1/PDL1 therapy, a promising new approach to treating cancer. Checkpoint inhibitors that enhance the immune system against PD-1 and PD-L1 show great promise, having substantially improved the prognosis for patients with several advanced cancers, including melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and head and neck cancer. As promising as they are, these therapies are also associated with a unique set of side effects, called immune-related adverse events (irAEs), believed to be the result of an immune system overstimulated by the therapy. While these side effects are generally treatable, they can in rare cases be very serious, even fatal. In addition, there’s currently no way to predict which patients will develop irAEs before starting treatment, requiring clinicians to watch and wait after treatment begins. Notably, the toxicity from checkpoint therapy does not appear to be associated with a patient’s cancer or their response to the treatment, supporting the idea that it is a patient-specific reaction. With a growing need to identify which patients are at risk for irAEs, investigators led by Joanne B. Weidhaas, MD, PhD, MSM, of UCLA Jonsson Comprehensive Cancer Center, vice chair Department of Radiation Oncology, and director Division of Molecular and Cellular Oncology at UCLA Health, examined DNA signatures in 99 patients, looking for patterns that would indicate if inherited DNA biomarkers would predict toxicity. In findings published in Journal for Immunotherapy of Cancer, they report that they were able to identify a biomarker panel that predicts toxicity with 80% accuracy. “These findings represent an important step toward personalizing checkpoint therapy, the use of which is growing rapidly,” said Dr. Weidhaas. “While we are still at the early stages of understanding the mechanisms by which these germline mutations regulate immunity and the systemic stress response, our repeated findings that these variant panels can predict systemic toxic responses to cancer therapy are potentially paradigm-shifting.” The authors of the study say applying these findings may improve clinicians’ ability to offer truly personalized cancer therapy by enabling consideration of toxicity along with other data that can predict patients’ response to treatment. “As the efficacy of cancer therapy improves, resulting in higher and higher rates of long-term cancer control,” they write, “cure without harm will only become an increasingly important endpoint.” Article: Weidhaas J, Marco N, Scheffler AW, et al. Germline biomarkers predicting toxicity to anti-PD1/PDL1 checkpoint therapy. Journal for ImmunoTherapy of Cancer 2021;0:e003625. doi:10.1136/ jitc-2021-003625 Funding: JW was supported by NCI Grant CA238998. Competing interests: JW has created intellectual property that was patented at Yale University and licensed to MiraDx, a company that she cofounded. MiraDx has developed miRSNP panels that were applied to blinded samples in this analysis. Journal

MiraDx Frequently Asked Questions (FAQ)

  • When was MiraDx founded?

    MiraDx was founded in 2008.

  • Where is MiraDx's headquarters?

    MiraDx's headquarters is located at 11600 Wilshire Blvd., Suite 410, Los Angeles.

  • What is MiraDx's latest funding round?

    MiraDx's latest funding round is Series A.

  • How much did MiraDx raise?

    MiraDx raised a total of $1M.

  • Who are the investors of MiraDx?

    Investors of MiraDx include Connecticut Innovations and Yale University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.